|
In situ Formation and NNNT increase over time
|
|
5
|
269
|
October 6, 2026
|
|
Issue Regarding Purchase of N-Nitroso N-Desmethyl Rosuvastatin Reference Standard
|
|
12
|
517
|
September 26, 2026
|
|
Theoretical evaluation of NDSRIs
|
|
13
|
654
|
September 25, 2026
|
|
Is Sensitivity really the biggest challenge or is it sample preparation?
|
|
1
|
194
|
September 24, 2026
|
|
N-Nitroso Abemaciclib
|
|
15
|
1192
|
September 14, 2026
|
|
Nitrosation of bilastine
|
|
7
|
341
|
September 9, 2026
|
|
👨💻 Dashboard Containing Published AI Limits
|
|
33
|
4659
|
September 8, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
8
|
782
|
September 7, 2026
|
|
An unexpected nitrosamine product of oclacitinib: Synthesis, structural elucidation, ADMET profiling and preliminary toxicological assessment-Pub
|
|
4
|
296
|
August 26, 2026
|
|
Approaching the Solid-Phase Reaction Limit: Nitrosation of 4-Phenylpiperidine Hydrochloride in Dense Slurries-Pub
|
|
0
|
112
|
August 20, 2026
|
|
From Detection to Prediction: AI-driven Process Analytical Technology for Nitrosamine and NDSRI Control in Pharmaceuticals-Pub
|
|
0
|
174
|
August 19, 2026
|
|
A Rapid and Sensitive LC–MS/MS Method for Quantification of NDSRI in Melatonin Drug Product via Controlled In Situ Formation-Pub
|
|
0
|
141
|
August 14, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
5
|
576
|
August 11, 2026
|
|
An Analytical Quality by Design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product-Pub
|
|
2
|
272
|
August 8, 2026
|
|
🛑 N-nitroso Ticagrelor
|
|
32
|
4464
|
August 8, 2026
|
|
Nitrosamine Control Strategy for Products within the Scope of ICH S9
|
|
5
|
367
|
August 7, 2026
|
|
N-Nitroso Desmethyl Tramadol - Standard
|
|
3
|
287
|
July 27, 2026
|
|
Complex versus simple N-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigms -Pub
|
|
8
|
801
|
July 25, 2026
|
|
Which Molecule Is Involved in the Nitrosation Reaction of Pharmaceuticals: NO or NO 2 ? -Pub
|
|
3
|
303
|
July 24, 2026
|
|
Trace-level LC–MS/MS quantification of two nitrosamine impurities formed from terazosin-related impurities in pharmaceutical products and greenness assessment-Pub
|
|
2
|
225
|
July 15, 2026
|
|
In Vitro Metabolism Study of NDSRIs
|
|
4
|
452
|
July 9, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
4
|
405
|
July 8, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
10
|
933
|
July 7, 2026
|
|
Analytical Challenges in Quantifier Ion Selection Due to Mass Error Variability
|
|
7
|
382
|
July 2, 2026
|
|
NDSRI growth with respect to age
|
|
12
|
602
|
June 25, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
326
|
June 19, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
5755
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
178
|
June 16, 2026
|
|
Finasteride NDSRI
|
|
2
|
199
|
June 15, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
348
|
June 1, 2026
|